Related Experiment Video
Updated: Nov 2, 2025
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.6K
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
Caterina Arru1, Maria Rosaria De Miglio2, Antonio Cossu3
1Department of Biomedical Sciences, University of Sassari, Viale San Pietro 43, 07100, Sassari, Italy.
Advances in Therapy
|June 9, 2021
Summary
The combination of durvalumab and tremelimumab shows some benefits over chemotherapy for certain solid tumors. However, it generally does not outperform durvalumab alone, necessitating further research with larger patient groups.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Cancer immunotherapy, particularly with agents targeting PD-L1 and CTLA-4, is a significant medical advancement.
- Durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) are key immunotherapeutic agents being investigated.
- The combination of these agents is under scrutiny for efficacy in solid tumors.
Purpose of the Study:
- To systematically review the existing scientific literature on the combination of durvalumab and tremelimumab in solid tumors.
- To assess the oncological advantages and limitations of this combined therapeutic approach.
Main Methods:
- A comprehensive digital literature search was conducted on Medline (PubMed) and Scopus databases.
- Searches included articles published up to February 26, 2021, using keywords 'durvalumab' and 'tremelimumab'.
- Inclusion criteria comprised English-language trials of adult patients with solid cancers treated with the combination therapy.
Main Results:
- The search yielded 267 results, with 19 articles ultimately included after exclusions, encompassing 2052 patients.
- The durvalumab and tremelimumab combination demonstrated certain oncological benefits compared to traditional chemotherapy in specific tumor subsets.
- Consistent advantages over durvalumab monotherapy were generally not observed.
Conclusions:
- The combination therapy shows promise in select cases but lacks consistent superiority over monotherapy.
- Methodological limitations in several studies highlight the need for future research.
- Well-designed clinical trials with larger patient cohorts are warranted to further evaluate this combination therapy.
Related Concept Videos
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
01:27Tumor Immunotherapy
791
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
791
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
01:30Cancer Vaccines
592
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
592
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
272
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
272
02:50Combination Therapies and Personalized Medicine
5.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K